Wuxi Jinghai (920547) uses 30 million yuan of its own funds to purchase financial products to improve the efficiency of using its own funds.

On March 26, Wuxi Jinghai Amino Acid Co., Ltd. announced that the total amount of its idle self-owned funds used to purchase financial products is 30 million yuan. As of now, the balance of unused idle self-owned funds for purchasing financial products that have not matured is 172 million yuan.

Wuxi Jinghai stated in the announcement that the company held the eighth meeting of the fourth board of directors and the annual shareholders’ meeting for 2024, where it approved the “Proposal on the Company’s Investment in Financial Products Using Idle Self-Owned Funds,” allowing the company to invest no more than 200 million yuan of its idle self-owned funds in financial products.

According to Wall Street Finance, the company is a national-level specialized and innovative “little giant” enterprise primarily engaged in the research and development, production, and sales of amino acid products. Its main products include branched-chain amino acids (isoleucine, valine, leucine), tryptophan, phenylalanine, proline, etc., which can be widely used in pharmaceuticals, food, health products, daily chemicals, and many other fields. The company’s downstream customers mainly come from the pharmaceutical sector, primarily comprising manufacturers of formulations and culture media, while others are used as raw materials for health products, cosmetics, and food.

The company’s amino acid products are sold in North America, Europe, and the Asia-Pacific region. Over years of operation, it has accumulated rich customer resources and established long-term stable cooperative relationships with well-known customers across different fields, including Nestlé, Abbott, Fresenius Kabi, Cytiva, and Prinova. After years of innovative development, the company has become one of the domestic enterprises with certain advantages in the large-scale production of amino acid products through biological manufacturing methods. The variety and production scale of the company’s amino acid raw material drug series rank among the top in the industry. The company is recognized as a high-tech enterprise, consistently adhering to technological innovation and relying on production, education, and research for technical support. It has established the Jiangsu Provincial Enterprise Technology Center, Jiangsu Provincial Amino Acid Engineering Technology Research Center, and an academician workstation, among others. The company aims for green development manufacturing and has developed a series of low ammonia nitrogen fermentation technologies. It has successively received honors such as “Demonstration Enterprise for Innovation Capability Construction of Small and Medium-sized Enterprises in Jiangsu Province,” “Demonstration Enterprise for Energy Conservation and Emission Reduction Technological Innovation in Jiangsu Province,” and “Advanced Collective for Technological Innovation in the Bio-fermentation Industry during the 13th Five-Year Plan.” Multiple products, including high-purity isoleucine and high-purity valine, have been recognized as high-tech products, and the “Jinghai” trademark has been recognized as a famous trademark in Jiangsu Province.

The company currently holds 14 registration certificates for amino acid raw material drugs and was the first in the industry to pass the 2010 version of China GMP certification in 2012. Due to the successful research, development, and production of a series of medicinal amino acids, the company has formed supporting capabilities and is one of the domestic enterprises with certain advantages in the large-scale production of amino acid products through biological manufacturing methods. The company has earned a good reputation among peers and customers, established a positive corporate image, and achieved high brand awareness, laying a solid market foundation for the company’s vigorous business expansion. The company currently holds 23 authorized invention patents and has hosted 2 national standards, 3 industry standards, and 1 group standard as the primary drafting unit, participating in the formulation of 3 industry standards and 2 group standards; it has received multiple awards including the Ministry of Education and Wuxi City Science and Technology Progress Award, and in 2018, it received the second prize in Jiangsu Province for Science and Technology.

Relying on its market position and competitive advantages in the sub-market of amino acid products, the company actively explores emerging markets both domestically and internationally, continues to expand its market share, and consolidates its market position; it is advancing the EU CEP certification and Japan MF registration certification work for its products, aiming to increase the international market share of amino acid raw materials. In the first half of 2025, the sales volume of its main products is expected to achieve certain growth, while the company has established a wholly-owned subsidiary in Singapore and plans to set up wholly-owned companies in the Netherlands and the United States later to further improve its global market layout.

In terms of performance, in 2025, the company achieved operating income of 406 million yuan, a year-on-year increase of 19.62%; the net profit attributable to shareholders of the listed company was 62.73 million yuan, a year-on-year increase of 46.39%.